ライフサイエンスコーパス: lymphoblastic lymphoma

1 ic background, display a high rate of thymic lymphoblastic lymphoma.

2 transformation to acute myeloid leukemia and lymphoblastic lymphoma.

3 ansformation to acute myeloid leukemia and T-lymphoblastic lymphoma.

4 The patient's diagnosis was T-lymphoblastic lymphoma.

5 lopment of human multiple myeloma and T-cell lymphoblastic lymphoma.

6 -cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.

7 e, were observed due to an aggressive T-cell lymphoblastic lymphoma.

8 ession, and a biopsy showed precursor B cell lymphoblastic lymphoma.

9 eas T/T(F) causes a long-latency, pre-B-cell lymphoblastic lymphoma.

10 (DK/DK) mice suffered from rapid-onset acute lymphoblastic lymphoma.

11 therapy was effective only in patients with lymphoblastic lymphoma.

12 cute lymphoblastic leukemia (ALL) and T-cell lymphoblastic lymphoma.

13 ke cell line established from a patient with lymphoblastic lymphoma.

14 similar to most human and mouse T-cell acute lymphoblastic lymphomas.

15 tical in the inception of human T cell acute lymphoblastic lymphomas.

16 s not detected in either case of precursor B-lymphoblastic lymphomas.

17 two Burkitt's lymphomas, and two precursor B-lymphoblastic lymphomas.

18 apsed Philadelphia chromosome-negative acute lymphoblastic lymphoma (ALL) is poor.

19 ts afflicted with this syndrome present with lymphoblastic lymphoma and a myeloproliferative disorder

20 omas), and 15 highly aggressive lymphomas (7 lymphoblastic lymphomas and 8 Burkitt's lymphomas).

21 rom small non-cleaved-cell lymphoma, 16 from lymphoblastic lymphoma, and five from large-cell lymphom

22 %, and 1% of small noncleaved cell lymphoma, lymphoblastic lymphoma, and large-cell cases, respective

23 pe of NHL that includes large-cell lymphoma, lymphoblastic lymphoma, and small noncleaved-cell lympho

24 th T-cell leukemia (T-ALL) or advanced stage lymphoblastic lymphoma (ASLL).

25 hich progressed to TdT(+)CD20(-) precursor B-lymphoblastic lymphoma (B-LBL).

26 All patients were treated with T-cell lymphoblastic lymphoma-Berlin-Frankfurt-Munster group (B

27 -cyclin-transgenic mice developed high-grade lymphoblastic lymphoma between 3 and 12 months of age.

28 -C3 mice develop aggressive malignant thymic lymphoblastic lymphomas between 4 and 8 months of age.

29 T-cell acute lymphoblastic lymphomas commonly demonstrate activating

30 he role of STATs in an IL-2-responsive human lymphoblastic lymphoma-derived cell line, YT.

31 he oncogenic potential of Stat5, with thymic lymphoblastic lymphomas developing in a significant prop

32 pstein-Barr virus-negative, precursor B cell lymphoblastic lymphoma diagnosed 6 months after transpla

33 omas, mantle cell lymphomas, and precursor B-lymphoblastic lymphomas) expressed significant levels of

34 Precursor B cell lymphoblastic lymphoma has not been previously reported

35 study, the genetic basis of GD/T-cell acute lymphoblastic lymphoma in 2 affected siblings was deciph

36 nt growth to Ba/F3 cells and caused a T-cell lymphoblastic lymphoma in a murine bone marrow transplan

37 The use of ASCT in adults with lymphoblastic lymphoma in first remission produced a tre

38 We observed an increased incidence of T-lymphoblastic lymphoma in Runx1(lacZ/lacZ) compared with

39 now report the development of thymic T cell lymphoblastic lymphomas in transgenic mice in which Stat

40 ent-free survival (pEFS) in pediatric T-cell lymphoblastic lymphoma is about 80%, whereas survival in

41 Lymphoblastic lymphoma (LBL) is a rare, clinically aggre

42 about the outcome of pediatric patients with lymphoblastic lymphoma (LBL) who suffer from progressive

43 lymphoblastic leukemia [ALL], 13 of 21 T-ALL/lymphoblastic lymphomas [LBL], 9 of 10 B-non-Hodgkin's l

44 been shown in patients with precursor T-cell lymphoblastic lymphoma/leukemia (pre-T LBL).

45 en during embryonic development and in acute lymphoblastic lymphoma-like biphenotypic acute leukemias

46 Therapy of lymphoblastic lymphoma (LL) has evolved with use of chem

47 lastic leukemia (ALL) therapy in adults with lymphoblastic lymphoma (LL).

48 rose after therapy for one case of T-lineage lymphoblastic lymphoma (LyL) and two cases of acute lymp

49 These mice developed lymphoblastic lymphomas of both T and B lineage, demonst

50 ing the truncated protein develop large-cell lymphoblastic lymphomas of T-cell origin.

51 was not seen in small-cell T-cell lymphomas, lymphoblastic lymphomas, or other tumor types, including

52 developed spontaneous tumors, predominantly lymphoblastic lymphomas, similar to p53(-/-) mice.

53 ce demonstrate complete penetrance of thymic lymphoblastic lymphomas, strongly suggesting that Prkdc

54 ctivation in adult mice induces T-cell acute lymphoblastic lymphoma (T-ALL), a tumor type known to ca

55 ntribute to the pathogenesis of T cell acute lymphoblastic lymphoma (T-ALL), but how activated Notch1

56 eviously, precursor T lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LyL) was found to express

57 oblastic leukemia (T-ALL) and 13 with T-cell lymphoblastic lymphoma (T-LBL) with nelarabine.

58 in approximately 15% of children with T-cell lymphoblastic lymphoma (T-LL).

59 e lymphoblastic leukemia (T-ALL) or advanced lymphoblastic lymphoma (T-NHL) were randomized at diagno

60 Pediatric T-cell lymphoblastic lymphomas (T-LBL) are commonly treated on

61 We examined 8 precursor T-cell lymphoblastic lymphomas (T-LBLs) and found significant B

62 reases of lymphoblasts to overt monoclonal T-lymphoblastic lymphomas that involved multiple organs.

63 cases of large cell lymphoma, five cases of lymphoblastic lymphoma, two cases of small, noncleaved-c

64 survival among the patients with early-stage lymphoblastic lymphoma was inferior to that among the pa

65 Tp53-deficient mouse model for T-cell acute lymphoblastic lymphoma, we reported that loss of heteroz

66 Fifteen patients with T-cell lymphoblastic lymphoma were also treated with the same h

67 Fourteen of 15 patients with T-cell lymphoblastic lymphoma were long-term survivors.

68 adult patients with newly diagnosed ALL and lymphoblastic lymphoma were treated with a dose-intense

69 n with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma who received one of three CNS-dir